Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dennis M Klinman

Showing results (1-10 of 141) with videos related to

Pageof 15
Sort By:
International Reviews of Immunology|July 5, 2006
Adjuvant activity of CpG oligodeoxynucleotidesDennis M Klinman
Expert Review of Vaccines|July 11, 2006
CpG oligonucleotides accelerate and boost the immune response elicited by AVA, the licensed anthrax vaccineDennis M Klinman
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 31, 2015
Therapeutic implications of orally delivered immunomodulatory oligonucleotidesDennis M Klinman
Expert Review of Vaccines|August 6, 2003
CpG DNA as a vaccine adjuvantDennis M Klinman
Expert Opinion on Biological Therapy|June 4, 2004
Use of CpG oligodeoxynucleotides as immunoprotective agentsDennis M Klinman
Nature Reviews. Immunology|April 2, 2004
Immunotherapeutic uses of CpG oligodeoxynucleotidesDennis M Klinman
Clinical Immunology (Orlando, Fla.)|October 31, 2003
Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primatesDaniela Verthelyi, Dennis M Klinman
Cancer Immunology, Immunotherapy : CII|February 15, 2011
CpG-conjugated apoptotic tumor cells elicit potent tumor-specific immunityHidekazu Shirota, Dennis M Klinman
Vaccine|April 30, 2009
A single-dose combination therapy that both prevents and treats anthrax infectionDennis M Klinman, Debra Tross
Expert Review of Vaccines|December 7, 2013
Recent progress concerning CpG DNA and its use as a vaccine adjuvantHidekazu Shirota, Dennis M Klinman
Pageof 15

Showing results (1-10 of 141) with videos related to

Sort By:
Pageof 15
International Reviews of Immunology|July 5, 2006
Adjuvant activity of CpG oligodeoxynucleotidesDennis M Klinman
Expert Review of Vaccines|July 11, 2006
CpG oligonucleotides accelerate and boost the immune response elicited by AVA, the licensed anthrax vaccineDennis M Klinman
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 31, 2015
Therapeutic implications of orally delivered immunomodulatory oligonucleotidesDennis M Klinman
Expert Review of Vaccines|August 6, 2003
CpG DNA as a vaccine adjuvantDennis M Klinman
Expert Opinion on Biological Therapy|June 4, 2004
Use of CpG oligodeoxynucleotides as immunoprotective agentsDennis M Klinman
Nature Reviews. Immunology|April 2, 2004
Immunotherapeutic uses of CpG oligodeoxynucleotidesDennis M Klinman
Clinical Immunology (Orlando, Fla.)|October 31, 2003
Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primatesDaniela Verthelyi, Dennis M Klinman
Cancer Immunology, Immunotherapy : CII|February 15, 2011
CpG-conjugated apoptotic tumor cells elicit potent tumor-specific immunityHidekazu Shirota, Dennis M Klinman
Vaccine|April 30, 2009
A single-dose combination therapy that both prevents and treats anthrax infectionDennis M Klinman, Debra Tross
Expert Review of Vaccines|December 7, 2013
Recent progress concerning CpG DNA and its use as a vaccine adjuvantHidekazu Shirota, Dennis M Klinman
Pageof 15